ArticleJournal of carcinogenesis2012
Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.
Article in Journal of carcinogenesis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Zinc in Prostate Health and Disease: A Mini Review.Biomedicines · 2022Review
- Article
- Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.Cancer reports (Hoboken, N.J.) · 2021Review
- Exploring a role for fatty acid synthase in prostate cancer cell migration.Small GTPases · 2021Article
- Review
- Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate Cancer to the Bone.Cancer research · 2021Article
- Overexpressing miR‑335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer.International journal of oncology · 2019Article
- Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics.Experimental and molecular pathology · 2018Article
- Investigation of the Anti-Prostate Cancer Properties of Marine-Derived Compounds.Marine drugs · 2018Review
- Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex.FEBS open bio · 2018Article
- Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production.Oncotarget · 2017Article
- The prostate response to prolactin modulation in adult castrated rats subjected to testosterone replacement.Journal of molecular histology · 2017Article
- ERG expression in prostate cancer: biological relevance and clinical implication.Journal of cancer research and clinical oncology · 2016Review
- Effects of Brassicaceae Isothiocyanates on Prostate Cancer.Molecules (Basel, Switzerland) · 2016Review
- Article
- Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis.The Journal of clinical investigation · 2015Article
- Transcriptional coregulators: emerging roles of SRC family of coactivators in disease pathology.Journal of molecular endocrinology · 2014Review
- MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.Molecular biology reports · 2014Article
- Nuclear receptor coactivators: master regulators of human health and disease.Annual review of medicine · 2014Review
- Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression.BMC medical genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is a leading cause of death among men in the United States, and currently early diagnosis and appropriate treatment remain key approaches for patient care. Molecularly prostate cancer cells carry multiple perturbations that generate malignant phenotype capable of uncontrolled growth, survival, and invasion-metastasis to other organs. These alterations are acquired both by genetic and epigenetic changes in tumor cells resulting in the activation of growth factor receptors, signaling proteins, kinases, transcription factors and coregulators, and multiple proteases required for the progression of the disease. Recent advances provide novel insights into the molecular functions of these oncogenic activators, implicating potential therapeutic targeting opportunities for the treatment of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.